Lilly challenges Teva patents for migraine med fremanezumab

Eli Lilly (NYSE:LLY) has filed for inter partes review of five patents owned by Teva Pharmaceutical Industries (NYSE:TEVA) covering migraine drug fremanezumab. Lilly's competing product is galcanezumab. Both antibodies are CGRP inhibitors.

Source: Bloomberg

 

More bad news for us!!!!

 

What does this mean for our launch in September?

 

These patents are similar to the patents upheld in Europe which have a chance to block Lilly from entering the market in the US (although it’s a long shot). Alder already settled with Teva and is paying Teva 5-7% royalties on revenues.

It’s not “more bad news for us” you idiot. If anything, the patent estate provides a potential source of upside.

 

uh "provides a potential source of upside".
who the hell talks like this? LOL

 

along with "patent estate"

Hey Carlton Banks (google the name), just going out on a limb here, but I'd guess you got picked on an awful lot in school.

 

LAUGHING MY ASS OFF !